1. Home
  2. VERU vs GLU Comparison

VERU vs GLU Comparison

Compare VERU & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • GLU
  • Stock Information
  • Founded
  • VERU 1971
  • GLU 2004
  • Country
  • VERU United States
  • GLU United States
  • Employees
  • VERU N/A
  • GLU N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • GLU Finance/Investors Services
  • Sector
  • VERU Health Care
  • GLU Finance
  • Exchange
  • VERU Nasdaq
  • GLU Nasdaq
  • Market Cap
  • VERU 108.8M
  • GLU 99.0M
  • IPO Year
  • VERU 1990
  • GLU N/A
  • Fundamental
  • Price
  • VERU $0.98
  • GLU $14.91
  • Analyst Decision
  • VERU Strong Buy
  • GLU
  • Analyst Count
  • VERU 4
  • GLU 0
  • Target Price
  • VERU $4.00
  • GLU N/A
  • AVG Volume (30 Days)
  • VERU 2.2M
  • GLU 12.4K
  • Earning Date
  • VERU 02-06-2025
  • GLU 01-01-0001
  • Dividend Yield
  • VERU N/A
  • GLU 8.60%
  • EPS Growth
  • VERU N/A
  • GLU N/A
  • EPS
  • VERU N/A
  • GLU 0.62
  • Revenue
  • VERU $16,886,419.00
  • GLU N/A
  • Revenue This Year
  • VERU N/A
  • GLU N/A
  • Revenue Next Year
  • VERU N/A
  • GLU N/A
  • P/E Ratio
  • VERU N/A
  • GLU $22.50
  • Revenue Growth
  • VERU 3.62
  • GLU N/A
  • 52 Week Low
  • VERU $0.36
  • GLU $11.61
  • 52 Week High
  • VERU $1.92
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • VERU 74.65
  • GLU 39.53
  • Support Level
  • VERU $0.70
  • GLU $14.62
  • Resistance Level
  • VERU $0.81
  • GLU $15.25
  • Average True Range (ATR)
  • VERU 0.11
  • GLU 0.32
  • MACD
  • VERU 0.02
  • GLU 0.01
  • Stochastic Oscillator
  • VERU 95.26
  • GLU 37.04

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: